Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 3/20 | 0.57 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.57 |
| ▸ | IKBKB | O14920 | 11/20 | 0.52 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.48 |
| ▸ | KDM6B | O15054 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614144 | 0.93 | CDC7 (0.54) | CDC7DBF4IKBKBLIMK1KDM6B | |
| SCHEMBL613690 | 0.90 | CDC7 (0.59) | CDC7DBF4IKBKBJAK2KDM4E | |
| SCHEMBL611071 | 0.88 | KDM6B (0.50) | CDC7DBF4IKBKBLIMK1KDM6B | |
| SCHEMBL613988 | 0.86 | KDM4E (0.50) | LIMK1KDM4EALDH1A1HPGD | |
| SCHEMBL612250 | 0.82 | IKBKB (0.70) | CDC7DBF4IKBKBJAK2CCNE1 | |
| SCHEMBL613639 | 0.81 | KDM6B (0.52) | CDC7DBF4LIMK1KDM6BKDM4C | |
| SCHEMBL614262 | 0.80 | CDC7 (0.65) | CDC7DBF4IKBKBKDM6BKDM4C | |
| SCHEMBL612320 | 0.79 | KDM4E (0.48) | KDM6BKDM4CKDM4EALDH1A1HPGD | |
| SCHEMBL614239 | 0.79 | CDC7 (0.59) | CDC7DBF4IKBKBJAK2CCNE1 | |
| SCHEMBL613433 | 0.77 | PTPN1 (0.48) | CDC7DBF4IKBKBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403857-B1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | CDC7 1/4885DBF4 593/4885IKBKB 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.